Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2026-03-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug (Emicizumab Injection). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company business activities that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-03-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies in Hong Kong to report monthly movements in securities, share capital, and public float. Since it does not fit into specific categories like 'Share Issue' (which usually refers to specific corporate actions) or 'Transaction in Own Shares' (which is a specific subset), and it is a recurring regulatory requirement for compliance, it is best classified as a Regulatory Filing (RNS).
2026-03-03 English
VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the FDA approval of a clinical trial for a specific drug product. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general regulatory announcement regarding business operations and product development that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2026-03-02 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 1% confidence The document is a formal list of the company's Board of Directors, their roles, and their committee memberships. This type of disclosure is standard for corporate governance reporting, specifically identifying the composition of the board and its committees. It does not announce a change in management (MANG), but rather provides a static snapshot of the current board structure, which falls under Governance Information.
2026-03-02 English
APPOINTMENT OF AN EXECUTIVE DIRECTOR
Board/Management Information Classification · 1% confidence The document is an official announcement from CSPC Pharmaceutical Group Limited regarding the appointment of a new Executive Director, Mr. Zhang Yiwei. It details his biographical information, professional background, and the terms of his service contract. This falls squarely under the category of board or management changes.
2026-03-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX for listed companies to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Earnings Release' or 'Annual Report' as it is a recurring compliance disclosure regarding share capital structure. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.